NASDAQ:CLLS Cellectis H1 2026 Earnings Report $2.81 +0.12 (+4.46%) As of 01:37 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Cellectis EPS ResultsActual EPS-$0.22Consensus EPS -$0.26Beat/MissBeat by +$0.04One Year Ago EPSN/ACellectis Revenue ResultsActual Revenue$6.90 millionExpected Revenue$11.05 millionBeat/MissMissed by -$4.15 millionYoY Revenue GrowthN/ACellectis Announcement DetailsQuarterH1 2026Date8/7/2026TimeAfter Market ClosesConference Call DateThursday, August 6, 2026Conference Call Time11:40AM ETConference Call ResourcesPress Release (6-K)Press ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(6-K)Press Release Cellectis Earnings HeadlinesCellectis Reports Financial Results for the Second Quarter 2026August 6 at 4:30 PM | globenewswire.comMonthly information on share capital and company voting rightsAugust 5 at 4:30 PM | globenewswire.comTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now.August 7 at 1:00 AM | Altimetry (Ad)Cellectis (CLLS) Projected to Release Earnings on ThursdayAugust 1, 2026 | americanbankingnews.comCellectis to Report Second Quarter Financial Results on August 6, 2026July 30, 2026 | globenewswire.comProlynx Names Simon Harnest as Chief Financial Officer and Amer Mirza, PhD, as Chief Scientific Officer as It Advances Multi-Program Obesity and Metabolic Disease PortfolioJuly 15, 2026 | globenewswire.comSee More Cellectis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Cellectis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cellectis and other key companies, straight to your email. Email Address About CellectisCellectis (NASDAQ:CLLS) is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors. The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies. Its pipeline includes multiple CAR‐T candidates, such as those targeting CD19 and CD22 antigens for B‐cell malignancies and other programs addressing acute myeloid leukemia. Cellectis advances these investigational therapies through preclinical research and early‐ to mid‐stage clinical trials, often in partnership with leading pharmaceutical firms to enhance development and commercialization capabilities. Cellectis operates research and process development laboratories as well as GMP manufacturing facilities across Europe and North America. Clinical trials are conducted in premier cancer centers in the United States and Europe, reflecting the company’s global reach. Strategic collaborations and licensing agreements support the expansion of its gene‐edited therapies into new indications and geographic markets, with an emphasis on scalable production and regulatory readiness. Under the leadership of founder and Chief Executive Officer Dr. André Choulika, Cellectis has established itself as a pioneer in TALEN‐based genome editing. The management team combines scientific and commercial expertise to drive innovation, with a focus on delivering next‐generation allogeneic CAR‐T therapies to patients worldwide.View Cellectis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Buy the Dip or Run: 3 Software Stocks Down 50% Face Their Moment of TruthSolventum Nears Inflection Point As It Begins to Unlock ValueBoeing's Comeback Is Building Momentum—Is It Real?Sandisk Just Delivered a Blowout Quarter—Here's Why the Stock Is FallingWestern Digital Stock Falls 12% Despite Beating Earnings EstimatesBed Bath & Beyond Renovates: The Neighborhood BlueprintAST SpaceMobile’s Latest BlueBird Launch Raises the Stakes Ahead of Q2 Earnings Upcoming Earnings Barrick Mining (8/10/2026)Simon Property Group (8/10/2026)SEA (8/11/2026)Cardinal Health (8/11/2026)Lumentum (8/11/2026)Cisco Systems (8/12/2026)NetEase (8/13/2026)Brookfield (8/13/2026)NU (8/13/2026)Applied Materials (8/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
